Physician profile
Todd Turner
NPI 1669933610
$1,151.68
in general payments reported to CMS, 2019-2025
15 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $139 · 2023: $227 · 2024: $531 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914 · Education: $98.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.27 |
| Education | $98.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $412.07 | 2022-2025 | |
| Abiomed | $116.01 | 2024-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.76 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $101.79 | 2024-2025 | Camzyos |
| Abbott Laboratories | $98.21 | 2024 | Ensite |
| Janssen Pharmaceuticals, INC | $81.63 | 2023-2024 | Xarelto |
| Amgen INC. | $65.05 | 2022-2024 | Repatha |
| Chiesi USA, INC. | $57.00 | 2022-2023 | Cleviprex, Kengreal |
| Novo Nordisk INC | $22.74 | 2024 | Ozempic |
| Lantheus Medical Imaging, INC. | $21.42 | 2023 | Definity |
| Boston Scientific Corporation | $15.34 | 2022 | |
| Cordis US Corp. | $15.01 | 2025 | Mynx Control Venous |
| Zoll Circulation INC | $15.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.65 | 2022 | |
| Medtronic, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.